PACE/State of FL - Register now – Sept. 10, 2025

Clinically relevant overview of key genetic factors, testing strategies, and post-result care.

Conflict is a natural part of human interaction, and the workplace is not immune from that experience.  Through this microlearning, we'll explore how proper conflict[...]

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Peter Lucas, M.D., Ph.D., vice chair of Research for the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic.

This three-part microlearning series is designed for healthcare professionals interested in understanding the diagnostic algorithms for celiac disease.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. They discuss how to proactively manage the variety of patient requests and interactions that occur in an outreach laboratory beyond the phlebotomy environment.

Mayo Clinic Laboratories’ BioPharma Diagnostics team supports companies from discovery to post-market in advancing their precision medicine initiatives. In this collaboration example, learn how BioPharma Diagnostics helped a biotech company complete a surveillance biomarker study to establish a cutoff for its assay developed to monitor the progression or regression of disease in patients with well-defined gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the widespread outbreaks of H5N1 bird flu and the new “FLiRT” variants of COVID-19.

William Morice II, M.D., Ph.D., president and chief executive officer of Mayo Clinic Laboratories, authored a Becker’s Healthcare article on how hospital laboratories can navigate times of change and uncertainty with the steadfast support of a business partner like Mayo Clinic Laboratories.

This week's research roundup feature: Monoclonal immunoglobulin (MIg) crystalline nephropathies are rare lesions resulting from precipitation of MIgs in the kidney as crystalline inclusions. They can be categorized into lesions with predominant intracellular crystals (light chain [LC] proximal tubulopathy, LC crystal-storing histiocytosis, LC crystalline podocytopathy] and lesions with predominant extracellular crystals (crystalglobulin-induced nephropathy, crystalline variant of LC cast nephropathy).

Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.

When patients are tasked with collecting specimens at home, the procedure can require special timing, collection steps, or storage conditions. If these aren’t clearly communicated to the patient beforehand, it can lead to confusion and unnecessary frustration. A laboratory can set up its patients for success by managing expectations when home collections are necessary. These steps can help ensure a successful experience for both patients and laboratory staff.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., interviews Douglas McMahon, M.D., from the Allergy and Asthma Center of Minnesota, to discuss how the lab supports asthma and allergy medical practice.

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

This week's research roundup feature: Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPNs) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for triple negative myelofibrosis (MF) patients who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes.